Compare · CERS vs RDDT
CERS vs RDDT
Side-by-side comparison of Cerus Corporation (CERS) and Reddit Inc. (RDDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CERS and RDDT operate in EDP Services (Technology), so they compete in similar markets.
- RDDT is the larger of the two at $35.76B, about 57.2x CERS ($625.2M).
- Over the past year, CERS is up 117.4% and RDDT is up 27.3% - CERS leads by 90.1 points.
- RDDT has been more active in the news (12 items in the past 4 weeks vs 7 for CERS).
- RDDT has more recent analyst coverage (25 ratings vs 4 for CERS).
- Company
- Cerus Corporation
- Reddit Inc.
- Price
- $3.12-1.58%
- $185.65+2.13%
- Market cap
- $625.2M
- $35.76B
- 1M return
- +15.99%
- +6.10%
- 1Y return
- +117.42%
- +27.31%
- Industry
- EDP Services
- EDP Services
- Exchange
- NASDAQ
- NYSE
- IPO
- 1997
- 2024
- News (4w)
- 7
- 12
- Recent ratings
- 4
- 25
Cerus Corporation
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation has collaboration with LifeSouth Community Blood Centers to manufacture INTERCEPT Fibrinogen Complex. The company was incorporated in 1991 and is headquartered in Concord, California.
Latest CERS
- Chief Executive Officer Jayaraman Vivek K sold $52,665 worth of shares (16,666 units at $3.16) as part of a pre-agreed trading plan, decreasing direct ownership by 0.74% to 2,232,211 units (SEC Form 4)
- Cerus Corporation to Release Second Quarter 2026 Financial Results on July 30, 2026
- Cerus Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Chief Financial Officer Green Kevin Dennis sold $99,105 worth of shares (33,676 units at $2.94) as part of a pre-agreed trading plan and gave a grant of 63,600 shares, decreasing direct ownership by 8% to 1,062,188 units (SEC Form 4) to cover withholding tax
- Chief Operating Officer Jayaraman Vivek K was granted 554,529 shares, gave a grant of 80,000 shares and sold $124,658 worth of shares (42,359 units at $2.94) as part of a pre-agreed trading plan, increasing direct ownership by 24% to 2,248,877 units (SEC Form 4) to satisfy withholding obligation
- Chief Legal Officer Jensen Chrystal gave a grant of 55,000 shares and sold $71,598 worth of shares (24,329 units at $2.94) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 966,657 units (SEC Form 4) (for withholding tax)
- President and CEO Greenman William Mariner gave a grant of 192,500 shares and sold $299,937 worth of shares (101,919 units at $2.94) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 5,053,036 units (SEC Form 4) to cover taxes
- Cerus to Showcase New Evidence, Innovation and Global Experience with the INTERCEPT Blood System at the 39th International ISBT Congress
- Director Bjerkholt Eric sold $53,180 worth of shares (20,454 units at $2.60), decreasing direct ownership by 7% to 261,679 units (SEC Form 4)
- Cerus Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation
Latest RDDT
- Chief Operating Officer Wong Jennifer L. exercised 39,167 shares at a strike of $5.35 and sold $7,750,173 worth of shares (39,167 units at $197.88) as part of a pre-agreed trading plan (SEC Form 4)
- CEO & President Huffman Steve Ladd exercised 18,000 shares at a strike of $25.29 and sold $3,561,471 worth of shares (18,000 units at $197.86) as part of a pre-agreed trading plan (SEC Form 4)
- Wedbush resumed coverage on Reddit with a new price target
- Reddit to Announce Second Quarter Results on Thursday, July 30, 2026
- Director Farrell Sarah E was granted 126 shares, increasing direct ownership by 1% to 9,862 units (SEC Form 4)
- Director Filikrushel Patricia was granted 122 shares, increasing direct ownership by 0.39% to 31,755 units (SEC Form 4)
- Director Gale Mary Porter was granted 107 shares, increasing direct ownership by 1% to 9,759 units (SEC Form 4)
- Director Habiger David C was granted 283 shares, increasing direct ownership by 0.77% to 37,264 units (SEC Form 4)
- Director Newhouse Steven O was granted 115 shares, increasing direct ownership by 0.88% to 13,187 units (SEC Form 4)
- Director Seibel Michael was granted 103 shares, increasing direct ownership by 2% to 5,436 units (SEC Form 4)